Table 4.
Distribution of malignant diseases by study period.⁎
| Diagnostic categories | Prepandemic (Jan 1–Feb 19)a |
P for difference | Pandemic (Feb 26–Apr 22) |
P for difference | Postpandemic (Apr 29–Jul 8)b |
P value a vs. b |
|---|---|---|---|---|---|---|
| Referrals (n = 384) | Referrals (n = 193) | Referrals (n = 450) | ||||
| Malignant neoplasms,n(%) | 82 (21.35) | <0.001 | 11 (5.70) | <0.001 | 121 (26.89) | 0.004 |
| Pancreatic cancer | 14 (3.65) | 0.117 | 2 (1.04) | 0.082 | 19 (4.22) | 0.190 |
| Lung cancer | 7 (1.82) | 1 (0.52) | 13 (2.89) | |||
| Colorectal cancer | 18 (4.69)† | 0.087 | 2 (1.04)† | 0.073 | 21 (4.67)† | 0.638 |
| Breast cancer | 4 (1.04) | 0 (0.00) | 5 (1.11) | |||
| Ovarian cancer | 6 (1.56) | 1 (0.52) | 9 (2.00) | |||
| Hepatocellular carcinoma | 1 (0.26) | 0 (0.00) | 2 (0.44) | |||
| Renal cell carcinoma | 2 (0.52) | 0 (0.00) | 4 (0.89) | |||
| Prostate cancer | 5 (1.30) | 1 (0.52) | 5 (1.11) | |||
| Mesothelioma | 1 (0.26) | 0 (0.00) | 2 (0.44) | |||
| Head and neck cancer | 2 (0.52) | 1 (0.52) | 3 (0.67) | |||
| Esophageal cancer | 1 (0.26) | 1 (0.52) | 4 (0.89) | |||
| Gastric cancer | 1 (0.26)† | 0 (0.00) | 2 (0.44)† | |||
| Endometrial and cervical cancer | 1 (0.26)† | 0 (0.00) | 1 (0.22) | |||
| Thyroid cancer | 1 (0.26) | 0 (0.00) | 1 (0.22) | |||
| Liposarcoma | 1 (0.26) | 0 (0.00) | 2 (0.44) | |||
| Bone sarcoma | 0 (0.00) | 0 (0.00) | 1 (0.22) | |||
| Neuroendocrine tumor | 1 (0.26) | 0 (0.00) | 1 (0.22) | |||
| Hodgkin and non-Hodgkin lymphoma | 13 (3.39) | 0.143 | 2 (1.04) | 0.072 | 22 (4.89) | 0.169 |
| Multiple myeloma | 1 (0.26) | 0 (0.00) | 1 (0.22) | |||
| Myelodysplastic syndrome | 0 (0.00) | 0 (0.00) | 1 (0.22) | |||
| Cancer of unknown primary site | 2 (0.52) | 0 (0.00) | 2 (0.44) |